Claims
- 1. A process for inhibiting T-cell proliferation in a mammalian host in need thereof by administering to said host an effective amount of at least one member selected from the group consisting of 2′-deoxyguanosine, prodrugs of 2′-deoxyguanosine and mixtures thereof, and at least one PNP inhibitor having a Ki of 50 nanomoles or less wherein said PNP inhibitor comprises 9-(3-pyridylmethyl)-9-deazaguanine.
- 2. The process of claim 1 wherein the PNP inhibitor is administered simultaneously with the at least one member or prior to the at least one member.
- 3. The process of claim 1 wherein the PNP inhibitor is administered up to about 1 hour prior to administering the at least one member.
- 4. The process of claim 1 which comprises orally administering the inhibitor.
- 5. The process of claim 4 which comprises administering the at least one member by infusion.
- 6. The process of claim 4 which comprises orally administering the at least one member.
- 7. The process of claim 1 wherein the at least one member is 2′-deoxyguanosine.
- 8. The process of claim 5 wherein the at least one member is 2′-deoxyguanosine.
- 9. The process of claim 6 wherein the at least one member is 2′-deoxyguanosine.
CROSS-REFERENCE TO RELATED APPLICATION
This application is the U.S. national phase of International Application No. PCT/US00/25306 filed Sep. 15, 2000, which claims priority from U.S. Provisional Patent Application Ser. No. 60/153,945 filed Sep. 15, 1999.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US00/25306 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO01/19375 |
3/22/2001 |
WO |
A |
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4985433 |
Secrist, III et al. |
Jan 1991 |
A |
4988702 |
Kostlan et al. |
Jan 1991 |
A |
5985848 |
Furneaux et al. |
Nov 1999 |
A |
6228847 |
Furneaux et al. |
May 2001 |
B1 |
Non-Patent Literature Citations (3)
Entry |
“A promising drug for mesothelioma”, Mikulski, S.M. et al., Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma, J. Clin. Oncol. 20, pp. 274-281 (2002). |
Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppresive agent, Shanta Bantia, et al.; International Immunopharmacology 1 pp. 1199-1210 (2001). |
“Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, seectively inhibits human T lympocytes” Greg A. Kicska, et al.; PNALS vol. 98, No. 8 pp. 4593-4598 (2001). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/153945 |
Sep 1999 |
US |